Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clover Health Investments, Corp. (Nasdaq: CLOV) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a publicly traded Medicare Advantage and healthcare technology issuer. Clover Health files reports with the U.S. Securities and Exchange Commission that describe its Medicare Advantage insurance operations, technology platform, financial performance, risk factors, and governance.
Investors can review current reports on Form 8-K, where Clover Health announces material events such as quarterly financial results, CMS Star Ratings for its Medicare Advantage PPO and HMO plans, and board or governance changes. Some 8-K filings also reference supplemental written responses to shareholder questions, offering additional context on strategy, cohort economics, and the role of Clover Assistant and Counterpart Health in the business.
In addition to 8-Ks, Clover Health’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) typically provide detailed discussions of its Insurance segment, Medicare Advantage membership trends, non-GAAP measures such as Adjusted EBITDA and Insurance Benefits Expense Ratio, and regulatory considerations related to Medicare, CMS Star Ratings, and value-based care arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how items such as Star Rating changes, CMS rate updates, or shifts in membership mix may affect Clover Health’s reported results. Users can also track insider transaction reports on Form 4 when they appear, to monitor equity transactions by directors and officers.
Filings are updated in near real time from the SEC’s EDGAR system, allowing investors, analysts, and other stakeholders to follow Clover Health’s evolving disclosures on Medicare Advantage performance, technology initiatives through Clover Assistant and Counterpart Health, and corporate governance developments.
Clover Health Investments director Anna U. Loengard reported an equity grant and updated share holdings. On January 6, 2026, she acquired 79,365 shares of Class A Common Stock at $0, representing time-based restricted stock units that will vest in full on the first anniversary of January 6, 2026, if she continues to serve as a director through that date. Following this award, she beneficially owns 527,456 Class A shares directly. She also reports indirect beneficial ownership of 27,600 Class A shares held in a custodial IRA for her son and 29,610 Class A shares held in a custodial IRA for her daughter, for which she serves as custodian.
Clover Health Investments, Corp. director William G. Robinson Jr reported an equity award of 79,365 shares of Class A common stock on January 6, 2026. These shares represent time-based restricted stock units that will vest in full on the first anniversary of January 6, 2026, as long as he continues to serve as a director through that date. The award was recorded at a price of $0 per share, reflecting a grant rather than an open-market purchase. After this grant, Robinson beneficially owned a total of 597,987 shares of Class A common stock in direct ownership.
Clover Health Investments, Corp. director Thomas L. Tran reported an equity award of Class A Common Stock. On January 6, 2026, he was granted 79,365 shares of Class A Common Stock, received as time-based restricted stock units (RSUs) at a price of $0 per share, meaning this was a compensatory grant rather than an open-market purchase.
According to the filing, these RSUs represent shares that will vest in full on the first anniversary of January 6, 2026, as long as Tran continues to serve as a director through that vesting date. After this award, Tran beneficially owns 180,029 shares of Class A Common Stock directly. This filing reflects routine director compensation in the form of equity.
Clover Health Investments, Corp. executive Jamie L. Reynoso, CEO for Medicare Advantage, reported a small insider sale of Class A common stock. On January 7, 2026, Reynoso sold 2,102 shares at a weighted average price of
An insider of CLOV has filed a Form 144 indicating an intent to sell 2,102 shares of common stock through broker Morgan Stanley Smith Barney LLC on or about January 7, 2026 on the NASDAQ. These shares were acquired on January 3, 2026 as restricted stock units from the issuer. The filing notes that 424,304,898 common shares were outstanding. Over the prior three months, the same seller completed additional common stock sales labeled as “10b5-1 Sales”.
Clover Health Investments, Corp. insider Jamie L. Reynoso, who serves as CEO, Medicare Advantage, reported a small open-market sale of company stock. On 12/18/2025, Reynoso sold 4,913 shares of Class A common stock at a weighted average price of $2.61 per share, with individual trade prices ranging from $2.58 to $2.64. The transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on March 13, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this sale, Reynoso beneficially owns 2,767,240 shares of Class A common stock, held in direct form.
Clover Health Investments, Corp.'s CEO for Medicare Advantage reported automatic share withholding transactions related to restricted stock unit vesting.
On December 14, 2025 and December 15, 2025, 12,567 and 8,691 shares of Class A Common Stock, respectively, were withheld at $2.7 per share to cover tax obligations when 6.25% quarterly tranches of time-based RSU grants from March 14, 2022 and September 16, 2022 vested. After these transactions, the officer directly beneficially owns 2,772,153 shares of Class A Common Stock, and the remaining RSUs continue to vest quarterly in 6.25% installments through March 14, 2026 and September 15, 2026, subject to continued service.
Clover Health Investments, Corp. reported an insider share withholding related to restricted stock vesting. On December 14, 2025, an officer serving as CEO, Counterpart Health had 98,411 shares of Class A common stock automatically withheld at $2.7 per share to cover tax obligations when a portion of previously granted restricted stock units vested.
After this transaction, the reporting person beneficially owned 1,051,674 Class A shares directly and 1,610,482 shares indirectly through a trust. The withheld shares correspond to 6.25% of the original time-based RSU grant made on March 14, 2022, which continues to vest in equal 6.25% quarterly installments through March 14, 2026, subject to continued service.
Clover Health Investments, Corp. reported an insider equity transaction by an officer serving as General Counsel & Secretary. On December 15, 2025, 6,404 shares of Class A common stock were withheld to cover tax obligations triggered by the vesting of time-based restricted stock units (RSUs).
The withheld shares correspond to 6.25% of the original RSU grant made on September 15, 2022. The remaining RSUs are scheduled to vest quarterly in equal 6.25% installments, with a final vesting date on September 15, 2026, subject to the reporting person’s continued service. Following this tax-withholding event, the reporting person beneficially owns 1,222,365 Class A shares directly.
Clover Health Investments Corp. insider tax withholding transaction
A Clover Health Investments Corp. officer, serving as General Counsel and Secretary, reported an automatic share withholding related to restricted stock units. On November 14, 2025, 7,459 shares of Class A common stock were withheld at a price of $2.47 per share to cover tax obligations triggered by the vesting of time-based restricted stock units granted on February 14, 2022. After this transaction, the reporting person beneficially owned 1,228,769 shares of Class A common stock. The underlying restricted stock units vest in quarterly installments of 6.25%, with the final vesting date scheduled for February 14, 2026, conditioned on continued service.
FAQ
What is the current stock price of Clover Health Investments (CLOV)?
What is the market cap of Clover Health Investments (CLOV)?
